Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 20/20 | 0.68 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.68 |
| ▸ | LPAR1 | Q92633 | 12/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.62 |
| ▸ | TSPO | P30536 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.62 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27128524 | 1.00 | LPAR2 (0.68) | LPAR2LPAR4LPAR1ADRB3TSPO | |
| SCHEMBL26907413 | 0.95 | LPAR2 (0.66) | LPAR2LPAR4LPAR1ADRB3TSPO | |
| SCHEMBL23519907 | 0.85 | LPAR2 (0.69) | LPAR2LPAR4LPAR1ADRB3TSPO | |
| SCHEMBL26907247 | 0.85 | LPAR2 (0.69) | LPAR2LPAR4LPAR1ADRB3TSPO | |
| SCHEMBL26907261 | 0.81 | LPAR2 (0.72) | LPAR2LPAR4LPAR1ADRB3TSPO | |
| SCHEMBL27115524 | 0.81 | LPAR2 (0.72) | LPAR2LPAR4LPAR1ADRB3TSPO | |
| SCHEMBL26907304 | 0.81 | LPAR2 (0.86) | LPAR2LPAR4LPAR1ADRB3TSPO | |
| SCHEMBL29936034 | 0.81 | LPAR2 (1.00) | LPAR2LPAR4LPAR1 | |
| SCHEMBL26907268 | 0.81 | LPAR2 (1.00) | LPAR2LPAR4LPAR1 | |
| SCHEMBL26907312 | 0.80 | LPAR2 (0.90) | LPAR2LPAR4LPAR1ADRB3TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4073073-B1 | THIENOPYRIMIDINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARM SPA (IT) | 2023-12-06 | — | — | EP | claimed |
| EP-4073073-A1 | THIENOPYRIMIDINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-10-19 | — | — | EP | claimed |
| EP-4073073-B1 | THIENOPYRIMIDINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARM SPA (IT) | 2023-12-06 | — | — | EP | disclosed |
| US-20230061417-A1 | THIENOPYRIMIDINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230061417-A1 | THIENOPYRIMIDINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | LPAR2, LPAR5, LPAR1 | LPAR2 1/4885LPAR4 5/4885LPAR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.